C-KIT expression in primary and metastatic merkel cell carcinoma

Meora Feinmesser*, Marisa Halpern, Ella Kaganovsky, Baruch Brenner, Eyal Fenig, Emmilia Hodak, Jaqueline Sulkes, Elimelech Okon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

61 Scopus citations


Merkel cell carcinoma (MCC) is an aggressive neuroendocrine tumor of the skin that is associated with a high incidence of recurrence and metastasis. The therapeutic arsenal for this malignancy is limited and once it spreads, there is no effective treatment, c-kit expression has been demonstrated previously in primary MCCs thus raising the possibility of treating MCCs with imatinib mesylate, the tyrosine kinase inhibitor that has shown promise in the management of c-kit expressing tumors. In this study we examine 25 additional primary MCCs and also 6 of their lymph node metastases. Formalin-fixed, paraffin-embedded tissues were stained immunohistochemically with an antibody directed against the KIT receptor. Percentage and intensity of staining were analyzed semiquantitatively using a three-tiered system. Twenty-one of the 25 (84%) primary tumors stained positively for KIT, of which 14 (67%) showed widespread positivity. Five of the 6 lymph nodes (83%) were similarly positive. High mitotic rate and vascular invasion in the primary tumors tended to be associated with prominent staining in the lymph node metastases. No association was found between c-kit expression and outcome. We confirm that the majority of primary MCCs express c-kit and further find that metastases are positive for the KIT receptor as well. Thus, c-kit expression may be an early event in the transformation of MCC, but not a marker for tumor progression.

Original languageEnglish
Pages (from-to)458-462
Number of pages5
JournalAmerican Journal of Dermatopathology
Issue number6
StatePublished - Dec 2004
Externally publishedYes


  • Merkel cell carcinoma
  • Tyrosine kinase inhibitors
  • c-kit


Dive into the research topics of 'C-KIT expression in primary and metastatic merkel cell carcinoma'. Together they form a unique fingerprint.

Cite this